Home/Filings/4/0001493152-23-033815
4//SEC Filing

van der Baan Bastiaan Jeroen 4

Accession 0001493152-23-033815

CIK 0001335105other

Filed

Sep 26, 8:00 PM ET

Accepted

Sep 27, 6:05 AM ET

Size

10.3 KB

Accession

0001493152-23-033815

Insider Transaction Report

Form 4
Period: 2023-09-26
Transactions
  • Award

    Options to Purchase Common Stock

    2023-09-26+250,000250,000 total
    Exercise: $1.95Exp: 2028-09-26Common (250,000 underlying)
  • Award

    Options to Purchase Common Stock

    2022-06-17+25,00025,000 total
    Exercise: $7.40From: 2022-06-17Exp: 2027-06-17Common (25,000 underlying)
  • Award

    Options to Purchase Common Stock

    2023-06-30+10,00010,000 total
    Exercise: $5.88From: 2023-06-30Exp: 2028-06-30Common (10,000 underlying)
Footnotes (1)
  • [F1]In connection with the Employment Agreement dated as of September 26, 2023 between the Company and the reporting person, the reporting person was granted stock options to purchase an aggregate of 250,000 shares of common stock, vesting quarterly over a three-year period commencing on the last day of each calendar quarter commencing October 1, 2023 until fully vested.

Documents

1 file

Issuer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CIK 0001335105

Entity typeother

Related Parties

1
  • filerCIK 0001938070

Filing Metadata

Form type
4
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 6:05 AM ET
Size
10.3 KB